<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cardiotoxicity of trastuzumab and other HER2-targeted agents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cardiotoxicity of trastuzumab and other HER2-targeted agents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cardiotoxicity of trastuzumab and other HER2-targeted agents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James P Morgan, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel F Hayes, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          Trastuzumab
         </a>
         is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2, also called ErbB2). For the 15 to 20 percent of patients with breast cancer whose tumors overexpress HER2, trastuzumab therapy is important in the treatment of both early and advanced disease. Its use, however, results in a small to modest risk for cardiotoxicity, which is typically manifested by an asymptomatic decrease in left ventricular ejection fraction and less often by clinical heart failure. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/773.html" rel="external">
          "Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Trastuzumab-based treatment'
         </a>
         .)
        </p>
        <p>
         In addition to
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , other HER2-targeted agents have been developed for treatment of HER2-overexpressing breast cancer including
         <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">
          ado-trastuzumab emtansine
         </a>
         (T-DM1),
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          fam-trastuzumab deruxtecan
         </a>
         ,
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         , and others. Although data are limited regarding cardiotoxicity in some of these newer agents, the available data support the view that these agents may be less cardiotoxic than trastuzumab. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p>
         Cardiotoxicity related to
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and related HER2-targeted agents will be presented here. The cardiotoxicity of other antineoplastic drugs, including anthracyclines and taxanes, management of heart failure, and clinical use of trastuzumab and other HER2-targeted therapies are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/773.html" rel="external">
          "Adjuvant systemic therapy for HER2-positive breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/767.html" rel="external">
          "Overview of the approach to metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/737.html" rel="external">
          "Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17017.html" rel="external">
          "Cancer survivorship: Cardiovascular and respiratory issues"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2782514468">
         <span class="h1">
          PATHOPHYSIOLOGY OF CARDIOTOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathophysiology underlying cardiac dysfunction in patients treated with agents targeting human epidermal growth factor receptor 2 (HER2) is not fully understood [
         <a href="#rid1">
          1,2
         </a>
         ]. Because many patients who receive
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         have previously received anthracyclines, it had been initially postulated that modification or exacerbation of anthracycline-related damage was responsible. However, endomyocardial biopsies from patients with trastuzumab-related cardiac dysfunction do not show typical anthracycline-related ultrastructural changes [
         <a href="#rid3">
          3
         </a>
         ]. In addition, trastuzumab-related cardiotoxicity may occur even in patients not exposed to anthracyclines [
         <a href="#rid4">
          4
         </a>
         ]. Further confounding the picture is that trastuzumab-related cardiotoxicity is not dependent on cumulative dose and may be largely reversible, and rechallenge with trastuzumab may be well tolerated.
        </p>
        <p>
         Evidence from both in vivo and in vitro studies indicate the importance of the epidermal growth factor (EGF) signaling system in the normal heart and suggest that cardiotoxicity associated with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         is directly related to HER2 blockade [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In animal models, HER2 signaling is important for embryonic cardiac development and myocyte survival as well as protection from potential cardiotoxins [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mice with ventricular-restricted knockout of the HER2 gene spontaneously develop signs of a dilated cardiomyopathy, and their cardiomyocytes show enhanced susceptibility to anthracycline-induced cell death [
         <a href="#rid9">
          9-12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although the role of HER2 in the pathophysiology of heart failure is not well understood, serum HER2 levels are increased in patients with chronic heart failure, and levels correlate inversely with left ventricular function [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The mechanism underlying the synergistic cardiotoxicity seen with anthracyclines and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         is unclear, but upregulation of HER2 expression by anthracyclines may contribute [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Other mechanisms for cardiotoxicity in patients treated with HER2-targeting agents may be operative since levels of HER2 in the adult heart are much lower than those found in breast cancer cells, the intended target of the anti-HER2-directed therapy. Furthermore,
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         , a dual kinase inhibitor of HER2 and epidermal growth factor receptor (EGFR), and
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         , a newer anti-HER2 monoclonal antibody that recognizes an epitope distant from that of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , appear to be only rarely associated with clinically-relevant cardiotoxicity. (See
         <a class="local">
          'Lapatinib'
         </a>
         below and
         <a class="local">
          'Pertuzumab'
         </a>
         below.)
        </p>
        <p>
         Newer data raise the possibility that
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         also interfere with the ligand-binding-induced cardioprotective pathways that are indispensable to recover from cardiac injury pathways and that differences in cardiotoxicity may reflect the different epitopes of HER2 that are recognized by individual antibodies [
         <a href="#rid16">
          16-19
         </a>
         ]. As an example, in one in vitro study, trastuzumab and pertuzumab (but not Erb-hcAb, a novel human antibody that recognizes a distinct epitope of HER2) inhibited assembly of the neuregulin 1/ErbB2/ErbB4 complex, which is required for cardiomyocyte survival [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H430527382">
         <span class="h1">
          TRASTUZUMAB
         </span>
        </p>
        <p class="headingAnchor" id="H39982900">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trastuzumab-related cardiotoxicity is most often manifested by an asymptomatic decrease in left ventricular ejection fraction (LVEF) and less often by clinical heart failure [
         <a href="#rid20">
          20-22
         </a>
         ]. In contrast to cardiotoxicity from anthracyclines, trastuzumab-related cardiotoxicity does not appear to be related to cumulative dose. It is often reversible with treatment discontinuation, and rechallenge is often tolerated after recovery. In addition, cardiac biopsy specimens after
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         exposure do not show significant myocyte destruction characteristic of anthracycline-induced dysfunction.
        </p>
        <p>
         These differences have led to the terms "Type I" and "Type II" chemotherapy-related cardiac dysfunction [
         <a href="#rid23">
          23
         </a>
         ]. Type I, associated with the anthracyclines, results, at least to some degree, in myocyte destruction and clinical heart failure. Type II, a phenomenon that is not unique to
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , is more often associated with a loss of contractility (presumably a form of stunning or hibernation) that is less likely to be associated with myocyte death or clinical heart failure and is more likely to be reversible.
        </p>
        <p class="headingAnchor" id="H39983118">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of trastuzumab-related cardiotoxicity varies according to patient-related factors, such as previous chemotherapy, pre-existing heart disease, and age [
         <a href="#rid24">
          24
         </a>
         ]. Data suggest that the risk for heart failure/cardiomyopathy among patients treated with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         exists but is low and may be limited by avoidance of cumulative doses of anthracycline exceeding 300 mg/m
         <sup>
          2
         </sup>
         . Despite this low risk, close cardiac monitoring is indicated. Further details are discussed below. (See
         <a class="local">
          'Cardiac monitoring'
         </a>
         below and
         <a class="local">
          'Acceptable concurrent treatment'
         </a>
         below.)
        </p>
        <p>
         The following data are available:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A modest incidence of trastuzumab-associated cardiotoxicity has been observed in large randomized trials of adjuvant
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. These trials required stringent and consistent cardiac monitoring, limited cumulative anthracycline dose to 300 mg/m
         <sup>
          2
         </sup>
         , and excluded patients with abnormal cardiac function (
         <a class="graphic graphic_table graphicRef70022" href="/z/d/graphic/70022.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid25">
          25-37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 2012 meta-analysis of randomized trials, altogether enrolling 11,991 women with HER2-positive early breast cancer, demonstrated that patients treated with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , relative to those who did not receive trastuzumab, experienced [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An increased risk for severe heart failure (2.5 versus 0.4 percent; relative risk [RR] 5.11, 90% CI 3.00-8.72)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A reduction in LVEF (RR 1.83, 90% CI 1.36-2.47)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There was no difference in the cardiotoxicity profile in trials with concurrent as compared to sequential administration of chemotherapy and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . A shorter treatment period (six months or less) did not appear to be associated with an increase in the risk of heart failure (RR 0.5, 95% CI 0.07-3.74), although the analysis was based on only one trial (FinHER).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent study including approximately 400 patients treated with
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         for node-negative disease demonstrated even lower rates of cardiotoxicity associated with trastuzumab relative to previous trials, with only 0.5 percent of patients developing grade 3 left ventricular systolic dysfunction and 3 percent of patients with asymptomatic LVEF decline [
         <a href="#rid39">
          39
         </a>
         ]. These modest increases in cardiotoxicity compare favorably with older trials, which evaluated trastuzumab in the setting of concurrent
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         exceeding 300 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Importantly, none of these trials reported a difference in the number of cardiac deaths between those who did versus did not receive an anthracycline. (See
         <a class="local">
          'Risk factors'
         </a>
         below and
         <a class="local">
          'Acceptable concurrent treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors associated with a higher likelihood of developing trastuzumab-related cardiotoxicity include age greater than 50 years and previous or concurrent anthracycline use, particularly among obese or overweight patients [
         <a href="#rid27">
          27,40,42-46
         </a>
         ]. By contrast, concurrent treatment with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and adjuvant radiation therapy does not increase the risk [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Other risk factors identified by multivariate analysis are pre-existing cardiac dysfunction (ie, decreased LVEF), older age, high body mass index (BMI), and antihypertensive therapy, while diabetes, valvular heart disease, and coronary artery disease did not significantly increase risk [
         <a href="#rid29">
          29,42,48
         </a>
         ]. On the other hand, at least a very small dataset suggests that diabetes is a risk factor for cardiotoxicity among older adult women receiving
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . In a study of 45 older adult women receiving trastuzumab either in the adjuvant setting or for metastatic disease, the risk of cardiotoxicity was 33 versus 6 percent for patients with and without diabetes, respectively [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/757.html" rel="external">
          "Overview of the approach to early breast cancer in older women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/761.html" rel="external">
          "Treatment of metastatic breast cancer in older women", section on 'HER2-positive disease'
         </a>
         .)
        </p>
        <p>
         The risk of trastuzumab-related cardiac dysfunction is highest in those patients who receive concurrent anthracyclines (especially if the cumulative
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         dose is &gt;300 mg/m
         <sup>
          2
         </sup>
         ); cardiac toxicity is modestly elevated for
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         given after anthracycline. By contrast, a lesser elevation has been observed to occur with trastuzumab given after a taxane [
         <a href="#rid1">
          1,26-31,40,41,50,51
         </a>
         ].
        </p>
        <p>
         Among patients receiving either anthracyclines or sequential treatment with anthracyclines and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         for breast cancer, being obese or overweight increases the risk of developing cardiac dysfunction (either symptomatic or asymptomatic, with a decline in ejection fraction). In a meta-analysis of 15 studies including approximately 8700 breast cancer patients treated with either anthracyclines or sequential anthracyclines and trastuzumab, the odds ratio (OR) for overweight patients (those with BMI &gt;25) for cardiac dysfunction was 1.38 (95% CI 1.06-1.80) relative to those with BMI &lt;25 [
         <a href="#rid46">
          46
         </a>
         ]. A higher magnitude of risk was observed among those who were obese (BMI ≥30; OR 1.47, 95% CI 0.95-2.28). Although this difference was not significant, this analysis consisted of far fewer patients compared with the one that included overweight patients.
        </p>
        <p>
         A cardiac risk score that includes age and baseline LVEF has been developed by investigators from the National Surgical Adjuvant Breast and Bowel Project (NSABP), based upon data from the NSABP B-31 trial, to predict the absolute risk of heart failure in individual patients [
         <a href="#rid48">
          48
         </a>
         ]. Others, using data from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, have developed a seven-factor risk score to predict three-year risk of heart failure or cardiomyopathy after
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         in Medicare populations [
         <a href="#rid52">
          52
         </a>
         ]. However, independent validation is needed before any of these tools can be considered for general use. (See
         <a class="local">
          'Reversibility and rechallenge'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14457353">
         <span class="h2">
          Reversibility and rechallenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trastuzumab-related cardiotoxicity is largely reversible in the majority of cases, and treatment continuation and/or resumption of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         after resolution of cardiac abnormalities may be safe in some women [
         <a href="#rid3">
          3,21,40,43,53,54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase III trial of chemotherapy with or without
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         conducted in women with metastatic breast cancer, 33 patients continued trastuzumab for a median of 26 weeks despite developing a cardiac event (most often an asymptomatic decline in LVEF) [
         <a href="#rid40">
          40,55
         </a>
         ]. The cardiac status of 28 patients (85 percent) improved or remained the same. Symptoms were reversible for 75 percent of those who received standard heart failure therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of 49 patients who developed trastuzumab-related cardiotoxicity, 79 percent of those who stopped
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         after developing symptomatic heart failure recovered with appropriate therapy [
         <a href="#rid53">
          53
         </a>
         ]. However, three patients did not recover, and one died of progressive heart failure. Treatment was reinitiated in 26 patients who interrupted trastuzumab for either an asymptomatic or symptomatic cardiac event, 16 (62 percent) of whom remained without evidence of subsequent cardiac toxicity. In patients with an asymptomatic reduction in LVEF, of whom 41 percent discontinued trastuzumab, LVEF recovered completely in 89 percent, with or without heart failure therapy. Even among the 10 patients who developed recurrent cardiac dysfunction after reintroduction, five were able to continue trastuzumab while maintaining a slightly reduced LVEF as the only sign of cardiotoxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reversibility was addressed in a seven-year follow-up analysis of the NSABP B-31 adjuvant
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         trial, in which patients with node-positive, HER2-positive breast cancer were randomly assigned to
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , followed by
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         with or without concurrent trastuzumab [
         <a href="#rid48">
          48
         </a>
         ]. The cumulative risk of a cardiac event (defined as definite or probable cardiac death or heart failure manifested by dyspnea with normal activity or at rest and associated with a decline in LVEF of &gt;10 percentage points from baseline to a value &lt;55 percent, or a decrease of &gt;5 percent to a value below the lower limit of normal) to seven years was 4.0 percent in the trastuzumab arm versus 1.3 percent in the non-trastuzumab arm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the 37 evaluable patients who received
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and met criteria for a cardiac event, one died because of heart failure. Of the remaining 36 patients, 33 were without symptoms of cardiac disease when assessed ≥6 months after their diagnosis of heart failure, although 21 continued to receive cardiac medications. LVEF measurements recovered to at least 50 percent in 21 patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of the 50 patients who were symptomatic but did not meet criteria for a cardiac event, 49 were observed for six months after onset of symptoms, and none reported symptoms of cardiac disease on last follow-up, although 12 continued to receive cardiac medication. Of the 114 evaluable patients with asymptomatic decline in LVEF during therapy who discontinued
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , 27 subsequently reported symptoms of possible cardiac disease. Of the remaining 87, LVEF was reported in 69 patients at least six months after discontinuation of trastuzumab, and only 15 still had an LVEF &lt;50 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The study authors developed a cardiac risk score including age and baseline LVEF to predict the absolute risk of heart failure in individual patients. When cardiac risk scores were plotted against a modeled heart failure risk curve, it was estimated that a 45-year-old woman with a baseline LVEF of 65 percent would have a 2.3 percent predicted risk of a cardiac event, whereas a 65-year-old woman with a baseline LVEF of 55 percent would have a 13 percent predicted risk [
         <a href="#rid56">
          56
         </a>
         ]. However, validation of this risk prediction tool is needed before it can be considered for use in general practice.
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14451472">
         <span class="h2">
          Clinical guidelines
         </span>
         <span class="headingEndMark">
          —
         </span>
         When
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         therapy is planned for patients in the adjuvant or metastatic setting, the patient's risk for trastuzumab-related cardiotoxicity should be carefully assessed and weighed against the benefits of trastuzumab treatment. In the adjuvant setting, trastuzumab therapy is likely to be held or discontinued for asymptomatic cardiac dysfunction, and thus baseline and serial screening of LVEF is appropriate. In the metastatic setting, the decision is more complex, given the clinical benefit provided by trastuzumab.
        </p>
        <p>
         Increased vigilance for signs and symptoms of cardiotoxicity is appropriate for higher-risk patients. Without clinical trials specifically evaluating cardiac monitoring and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         dosing with cardiotoxicity, we generally follow the protocols used in the cooperative group clinical trials of trastuzumab.
        </p>
        <p class="headingAnchor" id="H14451831">
         <span class="h3">
          Baseline evaluation and prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac function should be assessed prior to the initiation of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         therapy in both the adjuvant and metastatic settings [
         <a href="#rid20">
          20,57
         </a>
         ]. When treatment with trastuzumab follows use of an anthracycline, an assessment of LVEF should be done after completion of the anthracycline and prior to initiation of trastuzumab. Further details on the approach to patients also receiving anthracyclines are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         .)
        </p>
        <p>
         Patients with a normal baseline LVEF and no signs or symptoms of heart failure on physical examination may proceed with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         therapy. For such patients, unless there are other cardiac risk factors, we do not administer beta-blockers or angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, given toxicities and unknown effect on clinically significant heart failure or survival. In a phase III trial of 468 women with HER2-positive breast cancer treated with trastuzumab for 12 months, cardiotoxicity was comparable among those assigned to placebo,
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         (although there were fewer interruptions among those assigned to either treatment relative to placebo) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Patients with a modestly increased risk for cardiotoxicity include those with borderline LVEF (usually 40 to 50 percent), age &gt;50 years, and hypertension; they may proceed with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         after weighing the risks and benefits of trastuzumab therapy, but we and others recommend increased vigilance [
         <a href="#rid42">
          42,55
         </a>
         ] and management of comorbid conditions. Trastuzumab therapy is generally safe in patients with coronary artery disease and valvular disease but warrants careful monitoring.
        </p>
        <p>
         Noninvasive methods for LVEF estimation are discussed separately. Whichever method is selected for a baseline assessment should be continued for serial screening. (See
         <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">
          "Tests to evaluate left ventricular systolic function"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14452747">
         <span class="h3">
          Cardiac monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal surveillance for trastuzumab-related cardiotoxicity is not defined [
         <a href="#rid20">
          20
         </a>
         ]. In the adjuvant setting, we perform a baseline evaluation for cardiac function with a repeat at 3, 6, 9, and 12 months. Typically, in patients treated for metastatic disease, LVEF is monitored at baseline and then only in the presence of symptoms. In both the adjuvant and metastatic settings, clinical signs and symptoms, including increased heart rate or weight (≥2 kg in one week), edema, third heart sound (S3) gallop, or new dyspnea on exertion, should prompt further evaluation [
         <a href="#rid20">
          20,22,42
         </a>
         ].
        </p>
        <p>
         A retrospective study of over 19,000 women suggested that adjuvant
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         was associated with increased risk of heart failure during the period of adjuvant treatment but not thereafter, suggesting that routine intensive monitoring after treatment completion may not be necessary [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         While some evidence suggests troponin levels may have utility as a diagnostic and prognostic marker in trastuzumab-related cardiotoxicity [
         <a href="#rid60">
          60-62
         </a>
         ], data are still too limited to recommend their routine use.
        </p>
        <p class="headingAnchor" id="H95247366">
         <span class="h3">
          Dose adjustments for cardiotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         We follow the dosing guidelines for
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         as outlined in the clinical trials of adjuvant trastuzumab (NSABP B-31 trial and the NCCTG N9831 trial) [
         <a href="#rid28">
          28
         </a>
         ]. As discussed above, LVEF is infrequently monitored in the metastatic setting and instead is reserved for patients with suspicious symptoms or physical findings.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the LVEF declines 16 or more percentage points from baseline or 10 to 15 percentage points from baseline to below the lower limit of normal,
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         is withheld for four weeks, at which time the LVEF is reassessed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the LVEF remains below these levels,
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         should be discontinued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has symptomatic heart failure while receiving
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , trastuzumab should be discontinued. Symptomatic (clinical) heart failure is defined by the presence of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms (dyspnea, orthopnea, pedal edema)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Objective findings (elevated jugular venous pressure, sinus tachycardia, tachypnea, S3 gallop, crackles)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LVEF decline or chest radiograph findings of pulmonary edema or increased vascular markings
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14451604">
         <span class="h3">
          Heart failure treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trastuzumab-related cardiotoxicity usually responds to standard medical treatment for heart failure and discontinuation of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         in most, although not all, patients [
         <a href="#rid20">
          20,27,41,53
         </a>
         ]. Although treatment of trastuzumab-related cardiotoxicity has not been formally studied in clinical trials, standard medical therapy for heart failure, including beta blockers and angiotensin-converting enzyme inhibitors, should be initiated. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95247583">
         <span class="h3">
          Acceptable concurrent treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         As described above, the risk of trastuzumab-related cardiac dysfunction was significant when
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         was administered concurrently with anthracyclines [
         <a href="#rid41">
          41
         </a>
         ]. However, on further analysis, the risk began to increase when the cumulative
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         dose exceeded 300 mg/m
         <sup>
          2
         </sup>
         and was quite low at cumulative doses below 300 mg/m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
         There is accumulating evidence that concurrent administration of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         may be safe when the cumulative doxorubicin dose is limited to 180 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid35">
          35,63-65
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the FinHER trial, little cardiac toxicity (&lt;1 percent with symptomatic heart failure) was detected in those patients treated with adjuvant
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         administered prior to an anthracycline (trastuzumab for nine weeks with three cycles of adjuvant
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         followed by additional adjuvant chemotherapy with three cycles of
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [FEC]) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the NOAH trial, patients treated with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         (for a total duration of one year) concurrent with three cycles of
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (60 mg/m
         <sup>
          2
         </sup>
         ) and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (followed by additional neoadjuvant chemotherapy) had an incidence of symptomatic heart failure of less than 2 percent and any LVEF decrease of less than 3 percent [
         <a href="#rid35">
          35
         </a>
         ]. This was less than the incidence of trastuzumab-related cardiotoxicity in the adjuvant trials where trastuzumab was given concurrently with paclitaxel after completion of doxorubicin, which may have been due to the lower cumulative dose of doxorubicin in the NOAH trial. (See
         <a class="local">
          'Incidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         We avoid concurrent extended administration of anthracyclines and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         due to an increased risk of cardiotoxicity. Based upon data described above, trastuzumab concurrent with limited anthracyclines (≤3 cycles or ≤180 mg/m
         <sup>
          2
         </sup>
         of
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ) is a potentially safe option. However, there are no data that suggest improved efficacy if trastuzumab is given concurrent with anthracyclines rather than in sequence.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          Trastuzumab
         </a>
         in combination with a taxane, even after an anthracycline, shows low rates of symptomatic or severe cardiotoxicity [
         <a href="#rid26">
          26,41
         </a>
         ]. Likewise, trastuzumab is frequently administered concurrent with endocrine therapy and/or radiation therapy without significant cardiac toxicity [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H430527938">
         <span class="h1">
          LAPATINIB
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          Lapatinib
         </a>
         is an orally active tyrosine kinase inhibitor that affects both human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR, also called ErbB1). Early clinical studies suggest activity for lapatinib in women with advanced breast cancer, and there is some evidence that this drug, unlike
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , may penetrate the central nervous system and be effective against brain metastases. (See
         <a class="medical medical_review" href="/z/d/html/775.html" rel="external">
          "Brain metastases in breast cancer", section on 'HER2-positive disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer", section on 'Other tyrosine kinase inhibitor combinations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H430528262">
         <span class="h2">
          Incidence and clinical course
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emerging data suggest that
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         may have a more favorable cardiac safety profile than
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , even among patients who have previously received anthracyclines, taxanes, and trastuzumab:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase III trial, in which
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         was compared with capecitabine alone in women with advanced breast cancer who had progressed after treatment with regimens that included an anthracycline, a taxane, and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , treatment-related cardiac events were infrequent (4 of 155 receiving combined therapy compared with 1 of 145 patients treated with capecitabine alone) [
         <a href="#rid66">
          66
         </a>
         ]. Furthermore, three of the four were asymptomatic and not associated with a drop in left ventricular ejection fraction (LVEF). The fourth developed Prinzmetal angina, which resolved on discontinuation of lapatinib, but there was an unexplained subsequent drop in LVEF. There were no differences in the mean LVEF between treatment groups at the scheduled assessments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Global experience with lapatinib-related cardiotoxicity was reviewed in a pooled analysis of 3689 patients enrolled in clinical trials [
         <a href="#rid67">
          67
         </a>
         ]. Only 60 (1.6 percent) patients exposed to
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         had a cardiac event; 53 were asymptomatic declines in LVEF, and only 7 (0.2 percent) had symptoms of a decline in cardiac function. Furthermore, of the 552 patients previously treated with anthracyclines, only 12 (2.2 percent) had a decreased LVEF while on lapatinib, as did 14 (1.7 percent) of the 826 patients previously exposed to
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . The decrease in LVEF was rarely severe; the mean nadir was 43 percent. Of the 40 patients whose outcome was determined, 35 (88 percent) had partial or full recovery regardless of whether or not lapatinib was continued.
        </p>
        <p>
        </p>
        <p>
         Although these preliminary results compare favorably with historical experience of trastuzumab-related cardiotoxicity, the patients enrolled in these trials were highly selected. Additional clinical data and longer follow-up will be required to fully assess whether
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         has a more favorable cardiotoxicity profile than
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         .
        </p>
        <p class="headingAnchor" id="H430528277">
         <span class="h2">
          Combined lapatinib plus trastuzumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given their different mechanisms of action, investigators are beginning to combine
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         in an attempt to improve antitumor efficacy in HER2-overexpressing advanced breast cancer. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer", section on 'Lapatinib plus trastuzumab'
         </a>
         .)
        </p>
        <p>
         Despite initial concerns about the possibility of additive cardiotoxicity, the available evidence suggests that concurrent use of
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         is not incrementally more cardiotoxic than either drug alone [
         <a href="#rid68">
          68,69
         </a>
         ]. In the only randomized trial of lapatinib alone versus trastuzumab plus lapatinib in 296 patients with trastuzumab-refractory advanced breast cancer, the incidence of asymptomatic and symptomatic cardiac events was low with combination therapy (2 and 3.4 percent, respectively, compared with 0.7 and 1.4 percent, respectively, for lapatinib alone) [
         <a href="#rid68">
          68
         </a>
         ]. Importantly, all of the patients on this trial had received trastuzumab for a prolonged period, and those who developed heart failure during trastuzumab therapy were excluded. The rate of cardiotoxicity with the combination treatment in patients not previously exposed to trastuzumab is not yet known, but information should be available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00490139%3Fterm%3DALTTO%2Btrial&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSxi6SLWdl%2BnUNoX%2FW2n%2F9sQKe4uptC8RvyX%2BDM8Pe0awVqImXVlXSygXG5%2B0t9euz8%3D&amp;TOPIC_ID=774" target="_blank">
          ALTTO trial
         </a>
         . Nevertheless, clinical experience and follow-up duration are both limited.
        </p>
        <p class="headingAnchor" id="H430528296">
         <span class="h2">
          Guidelines for management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The US Food and Drug Administration-approved manufacturer's package insert recommends that a normal LVEF be confirmed prior to starting treatment with
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         and periodically during treatment. They advise discontinuation of lapatinib for a drop in the LVEF to &lt;50 percent, for those whose LVEF drops below the institution's lower limit of normal, and for any patients who develop clinical heart failure during therapy [
         <a href="#rid70">
          70
         </a>
         ]. Dose reduction is recommended if the LVEF recovers to normal after a minimum of two weeks and the patient is asymptomatic.
        </p>
        <p class="headingAnchor" id="H430528303">
         <span class="h1">
          ADO-TRASTUZUMAB EMTANSINE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">
          Ado-trastuzumab emtansine
         </a>
         (T-DM1) is an antibody-drug conjugate composed of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , a thioether linker, and a derivative of the antimitotic agent, maytansine. T-DM1 is used in metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, as well as for the adjuvant treatment of patients with HER2-positive disease who did not achieve a complete pathologic response to neoadjuvant therapy. The following information represents available data regarding cardiotoxicity with T-DM1 in advanced HER2-positive disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a pooled analysis of 1961 patients exposed to T-DM1, the total cardiac event rate (including any-grade congestive heart failure, left ventricular ejection fraction [LVEF] drops, acute cardiac ischemia, or cardiac arrhythmia) was 3.4 percent, mostly involving asymptomatic LVEF drops [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase III study compared T-DM1 versus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         in 991 patients with advanced HER2-overexpressing breast cancer that had previously been treated with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and a taxane [
         <a href="#rid72">
          72
         </a>
         ]. LVEF was assessed at baseline, weeks 6 and 12, and every 12 weeks thereafter. At a median 13-month follow-up, 8 of 481 patients in the T-DM1 group (1.7 percent) had an LVEF that was &lt;50 percent and at least 15 percentage points below baseline (versus 7 of 445 in the lapatinib/capecitabine group [1.6 percent]). Only three patients in each group had a decrease from baseline to &lt;40 percent, and only one patient receiving T-DM1 developed grade 3 left ventricular systolic dysfunction (symptomatic, responsive to intervention).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II randomized trial of first-line T-DM1 versus
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         in 137 patients with HER2-positive metastatic or locally advanced breast cancer, there were no reports of symptomatic heart failure [
         <a href="#rid73">
          73
         </a>
         ]. At a median follow-up of 23 months, three patients in each group had an asymptomatic decline in LVEF. There were three patients with a decline in LVEF ≤40 percent, two in the trastuzumab/docetaxel group (both of whom had received prior adjuvant anthracycline-based chemotherapy), and one who received T-DM1 (who had not received prior anthracycline and had no prior cardiac history).
        </p>
        <p>
        </p>
        <p>
         Given the favorable safety profile in advanced disease, the use of T-DM1 is of interest in early-stage disease, in which T-DM1 could potentially replace
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         plus a taxane. The tolerability of one year of T-DM1 after anthracycline-based chemotherapy was suggested in a trial in which 153 patients with HER2-positive early breast cancer and a prechemotherapy LVEF ≥55 percent received neoadjuvant
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         and cyclophosphamide (FEC) followed by T-DM1 for four cycles; patients could then receive three or four cycles of optional
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         with or without trastuzumab [
         <a href="#rid74">
          74
         </a>
         ]. T-DM1 was then resumed with optional radiotherapy for a total of one year of HER2-directed therapy. At a median follow-up of 25 months, four patients had asymptomatic LVEF declines (≥10 percentage points from baseline to &lt;50 percent), which led to discontinuation of T-DM1 in only one patient. There were no other prespecified cardiac events or episodes of symptomatic heart failure. This study was performed as a pilot to precede testing of T-DM1 in a more formal, future adjuvant trial. T-DM1 should not be used in the adjuvant setting unless large randomized trial results are available showing benefit in this setting.
        </p>
        <p>
         Importantly, all of these trials have a limited follow-up duration.
        </p>
        <p class="headingAnchor" id="H5088811">
         <span class="h2">
          Guidelines for management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The US Food and Drug Administration-approved prescribing information recommends that all patients treated with T-DM1 have LVEF assessed at treatment initiation and at regular intervals (eg, every three months) during treatment [
         <a href="#rid75">
          75
         </a>
         ]. At least temporary discontinuation of therapy is recommended if the LVEF falls to &lt;40 percent or is 40 to 45 percent with a ≥10 percent absolute decrease below the pretreatment value.
        </p>
        <p class="headingAnchor" id="H430528311">
         <span class="h1">
          PERTUZUMAB
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          Pertuzumab
         </a>
         is a monoclonal antibody that binds to a different epitope of the human epidermal growth factor receptor 2 (HER2) extracellular domain than does
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , and it prevents HER2 homo- and heterodimerization with other HER-family receptors. While initial studies showed limited activity for women with HER2-negative metastatic breast cancer, subsequent data demonstrate benefit when it is combined with trastuzumab for women with HER2-positive disease who had progressed on prior trastuzumab treatment, and in the first-line setting, in combination with trastuzumab and
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer", section on 'Trastuzumab plus pertuzumab plus a taxane'
         </a>
         .)
        </p>
        <p>
         Cardiotoxicity of combined therapy has been addressed in the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II trial of
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         in 66 patients with HER2-overexpressing breast cancer that progressed during prior trastuzumab therapy, only three patients had a decrease in left ventricular ejection fraction (LVEF) of ≥10 percentage points and less than a 50 percent value, and no patient experienced symptomatic cardiac toxicity [
         <a href="#rid76">
          76
         </a>
         ]. Two patients, one with an LVEF drop of 25 percentage points and the other by 13 percentage points, both recovered without treatment interruption, and both continued to receive pertuzumab and trastuzumab. The third patient with a decline of 14 percentage points in LVEF remained asymptomatic but withdrew from the study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The phase III CLEOPATRA trial randomly assigned 808 patients with HER2-positive breast cancer to first-line treatment with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         plus either
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         or placebo [
         <a href="#rid77">
          77
         </a>
         ]. Combined therapy with pertuzumab and trastuzumab was not associated with significantly worse cardiotoxicity. Among patients in whom LVEF was assessed after the baseline assessment, a decline of ≥10 percentage points that resulted in an LVEF of &lt;50 percent occurred in 3.8 percent of the pertuzumab group versus 6.6 percent of the control group. Notably, 72 percent of patients on the placebo arm and 87 percent of those on the pertuzumab arm recovered to a value of ≥50 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5088825">
         <span class="h2">
          Guidelines for management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Flookup.cfm%3Fsetid%3D17f85d17-ab71-4f5b-9fe3-0b8c822f69ff&amp;token=pEhTXp%2BFvKDGqjnfA4Q1mLck9tKOScNF7ZThGCZuM5btpGG7yCtK357SMYBIzZtNsRe4w5QRazj4%2FGPhAl0Y0%2F%2Fg%2FdByH6mw8wvMZ%2FOwqV8HiiZ2t3e8GfHkBXSuMqlf&amp;TOPIC_ID=774" target="_blank">
          US Food and Drug Administration-approved prescribing information
         </a>
         recommends that all patients treated with
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         have LVEF assessed at treatment initiation and at regular intervals (eg, every three months in the metastatic setting and every six weeks in the neoadjuvant setting) during treatment. If LVEF is &lt;45 percent, or is 45 to 49 percent with a ≥10 percent absolute decrease below the pretreatment value, withhold both pertuzumab and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and repeat LVEF assessment within approximately three weeks. Discontinue pertuzumab and trastuzumab if the LVEF has not improved or has declined further, unless the benefits for the individual patient outweigh the risks.
        </p>
        <p class="headingAnchor" id="H947351600">
         <span class="h1">
          FAM-TRASTUZUMAB DERUXTECAN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fam-trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor [
         <a href="#rid78">
          78
         </a>
         ]. It is appropriate for adult patients with unresectable or metastatic HER2-positive breast cancer who have received multiple anti-HER2-based regimens in the metastatic setting. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer", section on 'Fam-trastuzumab deruxtecan'
         </a>
         .)
        </p>
        <p>
         In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received fam-trastuzumab deruxtecan, two cases (0.9 percent) of asymptomatic left ventricular ejection fraction (LVEF) decrease were reported [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H834337766">
         <span class="h2">
          Guidelines for management
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F761139s000lbl.pdf&amp;token=M3JxtL3ViXvsfY2zBoWYi8%2FhggB4UAeaUP3t5Pe3aQ8woxCoTlVu0yhAlTNp5xFzSU%2BRQ1gcMQMFyk5Uok2G8vCJrw2%2BhTXYcJtIQuZivIE%3D&amp;TOPIC_ID=774" target="_blank">
          US Food and Drug Administration-approved prescribing information
         </a>
         , clinicians should assess LVEF prior to initiation of fam-trastuzumab deruxtecan, and at regular intervals during treatment, as clinically indicated. Our approach is to assess at baseline and for symptoms concerning for heart failure.
        </p>
        <p>
         Clinicals should permanently discontinue fam-trastuzumab deruxtecan if LVEF drops to less than 40 percent, or decreases from baseline of more than 20 percent; or if patients experience symptomatic congestive heart failure [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Treatment with fam-trastuzumab deruxtecan has not been studied in patients with a history of clinically significant cardiac disease or LVEF &lt;50 percent prior to initiation of treatment.
        </p>
        <p class="headingAnchor" id="H3272331720">
         <span class="h1">
          MARGETUXIMAB
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="130372" href="/z/d/drug information/130372.html" rel="external">
          Margetuximab
         </a>
         is an Fc-engineered anti-HER2-receptor monoclonal antibody that is US Food and Drug Administration approved, in combination with chemotherapy, for treatment of metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [
         <a href="#rid80">
          80
         </a>
         ]. In SOPHIA, left ventricular dysfunction occurred in 1.9 percent of patients treated with margetuximab [
         <a href="#rid81">
          81
         </a>
         ]. This agent has not been evaluated in patients with a pretreatment left ventricular ejection fraction (LVEF) value of &lt;50 percent, a prior history of myocardial infarction or unstable angina within six months, or congestive heart failure New York Heart Association class II to IV.
        </p>
        <p>
         As for other agents used in metastatic disease, our approach is to assess at baseline and subsequently only for symptoms concerning for heart failure. However, according to the United States Prescribing Information, baseline LVEF measurement should occur within four weeks prior to initiation of treatment, and every three months during and upon completion of treatment [
         <a href="#rid80">
          80
         </a>
         ]. It advises to withhold the agent for ≥16 percent absolute decrease in LVEF from pretreatment values, or LVEF value below institutional limits of normal (or 50 percent, if no limits are available) and ≥10 percent absolute decrease in LVEF from pretreatment values. The reason for our difference in monitoring relative to the prescribing information is reluctance to withhold treatment that is effectively controlling a patient's cancer in the absence of symptoms of heart failure.
        </p>
        <p class="headingAnchor" id="H3796998266">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">
          "Society guideline links: Breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H178451705">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/877.html" rel="external">
          "Patient education: Treatment of early HER2-positive breast cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trastuzumab
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         is associated with a risk of cardiac toxicity that is mechanistically distinct from that caused by anthracyclines. Trastuzumab-related cardiotoxicity is typically manifested by an asymptomatic decrease in the left ventricular ejection fraction (LVEF) and less commonly by clinical heart failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Previous or concurrent anthracycline use and age greater than 50 years are the strongest risk factors for development of trastuzumab-related cardiotoxicity. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the adjuvant setting, a baseline assessment prior to starting
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         and serial LVEF monitoring (at 3, 6, and 12 months after initiating trastuzumab and 18 months after initiating an anthracycline or other chemotherapy) are appropriate to screen for cardiac dysfunction. (See
         <a class="local">
          'Baseline evaluation and prevention'
         </a>
         above and
         <a class="local">
          'Cardiac monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the metastatic setting, after a baseline assessment, LVEF is infrequently monitored in the absence of symptoms. (See
         <a class="local">
          'Baseline evaluation and prevention'
         </a>
         above and
         <a class="local">
          'Cardiac monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Guidelines for
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         dosing for patients who develop trastuzumab-related cardiotoxicity are based upon the reduction in LVEF and patient symptoms. (See
         <a class="local">
          'Dose adjustments for cardiotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Trastuzumab-related cardiotoxicity is reversible in many patients and responds to standard treatment for heart failure. Many patients tolerate continued treatment or rechallenge with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . (See
         <a class="local">
          'Reversibility and rechallenge'
         </a>
         above and
         <a class="local">
          'Heart failure treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          Trastuzumab
         </a>
         can be safely administered with taxanes, radiation therapy, and endocrine therapy. (See
         <a class="local">
          'Acceptable concurrent treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other HER2-targeted agents
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast to
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , the risk of cardiotoxicity seems to be less with other human epidermal growth factor receptor 2 (HER2)-targeted agents, such as
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">
          ado-trastuzumab emtansine
         </a>
         (T-DM1), and
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         . Nonetheless, experience with all three of these agents is limited, and there is a potential risk of cardiotoxicity with all agents. (See
         <a class="local">
          'Lapatinib'
         </a>
         above and
         <a class="local">
          'Ado-trastuzumab emtansine'
         </a>
         above and
         <a class="local">
          'Pertuzumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A baseline assessment of LVEF is appropriate. As with
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , in the metastatic setting, LVEF is infrequently monitored during therapy in the absence of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Guidelines are available regarding dose adjustment in patients who develop cardiotoxicity during therapy with these agents. (See
         <a class="local">
          'Guidelines for management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Levine MN. Trastuzumab cardiac side effects: only time will tell. J Clin Oncol 2005; 23:7775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820.
          </a>
         </li>
         <li class="breakAll">
          Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium, December 14, 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med 2012; 367:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erickson SL, O'Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124:4999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 2005; 289:H1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99:8880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu FF, Stone JR, Schuldt AJ, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2005; 289:H660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perik PJ, de Vries EG, Gietema JA, et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007; 9:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chien KR. Herceptin and the heart--a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43:2046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fedele C, Riccio G, Malara AE, et al. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 2012; 134:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 2008; 44:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010; 106:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiúza M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther 2009; 26 Suppl 1:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry ML, Niu J, Zhang N, et al. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging 2018; 11:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Advani PP, Ballman KV, Dockter TJ, et al. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 2016; 34:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28:3416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29:3366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 2014; 32:2159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27:6129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; :CD006243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dang C, Guo H, Najita J, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol 2016; 2:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rastogi P, Jeoung J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel (T) versus AC-T with trastuzumab (H). J Clin Oncol 2007; 25S: ASCO #LBA513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guenancia C, Lefebvre A, Cardinale D, et al. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol 2016; 34:3157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27:2638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:3792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28:3422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014; 3:e000472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24:4107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eiger D, Pondé NF, Agbor-Tarh D, et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer 2020; 122:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripathy D, Seidman A, Keefe D, et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004; 5:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer EL, Lin NU. Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab? J Clin Oncol 2012; 30:3769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox KF. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy. Br J Cancer 2006; 95:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol 2019; 73:2859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldhar HA, Yan AT, Ko DT, et al. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. J Natl Cancer Inst 2016; 108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28:3910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 2010; 28:3901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol 2017; 35:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi G, Albanell J, Eiermann W, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003; 9:5944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semiglazov V, Gianni L, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. J Clin Oncol 2007; 25S: ASCO #532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27:5685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer 2013; 133:2245.
          </a>
         </li>
         <li class="breakAll">
          Lapatinib tablets. United States Prescribing Information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808 (Accessed on February 05, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pondé N, Ameye L, Lambertini M, et al. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer 2020; 126:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol 2015; 33:1136.
          </a>
         </li>
         <li class="breakAll">
          Ado-trastuzumab emtansine, for injection. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013; 18:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382:610.
          </a>
         </li>
         <li class="breakAll">
          Fam-trastuzumab deruxtecan-nxki, for injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf (Accessed on January 28, 2020).
         </li>
         <li class="breakAll">
          Margetuximab-cmkb injection. United States Prescribing Information. US National Library of Medicine. https://www.margenza.com/pdf/prescribing-information.pdf (Accessed on December 18, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugo HS, Im SA, Cardoso F, et al. SOPHIA Study Group. Phase 3 SOPHIA study of margetuximab + chemotherapy versus trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Second interim overall survival analysis. Cancer Res 2020; 80S: SABCS #GS1-02.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 774 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258081" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Trastuzumab cardiac side effects: only time will tell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17611206" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trastuzumab--mechanism of action and use in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258084" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258084" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23190227" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ERBB2 inhibition and heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7477377" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Requirement for neuregulin receptor erbB2 in neural and cardiac development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9362461" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7477376" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984589" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : ErbB2 is essential in the prevention of dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863464" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12072561" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15833803" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16860598" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Serum HER2 levels are increased in patients with chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16495390" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Herceptin and the heart--a molecular modifier of cardiac failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17719768" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22674190" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18430438" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19632177" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056944" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12237930" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Trastuzumab-associated cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14722042" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical cardiac tolerability of trastuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19669637" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15860848" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30092967" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26392097" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17638068" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530275" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236738" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18250349" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17208639" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21991949" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Adjuvant trastuzumab in HER2-positive breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21768458" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22042958" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24912899" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113825" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738535" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917839" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513938" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Trastuzumab containing regimens for early breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26539793" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11248153" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11870163" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cardiac dysfunction in the trastuzumab clinical trials experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18484781" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cardiotoxicity profile of trastuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel (T) versus AC-T with trastuzumab (H)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17646669" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22949432" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27458291" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19349549" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22987084" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828361" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530280" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236737" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24584736" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16908934" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32203207" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507176" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22987088" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060943" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31171092" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26476433" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679614" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679626" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28199174" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14676119" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19884557" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17192538" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18533085" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124187" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23629633" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23629633" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31923729" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23020162" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Trastuzumab emtansine for HER2-positive advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23382472" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25713436" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25713436" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124182" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23475636" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31825192" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31825192" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31825192" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : SOPHIA Study Group. Phase 3 SOPHIA study of margetuximab + chemotherapy versus trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
